Nancy, France, May 22, 2023 — The Centre Hospitalier Régional Universitaire (CHRU) de Nancy, one of the leading research institutions in France, announced it is partnering with TriNetX to attain access to global real-world data (RWD) to generate real-world evidence (RWE) in support of investigator-initiated research, as well as provide greater opportunities for its patients to attain access to innovative therapies through industry-sponsored clinical trials.
“Investigators at CHRU de Nancy will utilize the TriNetX platform to assess real-world healthcare strategies, collaborate with peers, and connect clinical trial opportunities from pharmaceutical companies with patients in need,” said Nathalie Thilly, Professor of Epidemiology and Public Health, Head of the Health Data Center, CHRU de Nancy.
“CHRU de Nancy’s Centre d’Investigation Clinique Plurithématique (CIC-P) is responsible for clinical and translational research, and most of the scientific production in this field comes from cohort studies and clinical trials within research involving human subjects,” said Nicolas Girerd, Professor of Therapeutics, Cardiologist, Head of the CIC-P, CHRU de Nancy. “The TriNetX platform complements these classic research capabilities by adding a massive dimension: access to global anonymized real-world data that is indispensable for generating real-world evidence by our clinical researchers.”
TriNetX is the largest and fastest-growing collaborative research network comprised of healthcare organizations and life sciences companies driving real-world research to accelerate the development of new therapies. TriNetX puts the power of RWD into the hands of its global community to improve protocol design, streamline trial operations, refine safety signals, and enrich RWE generation.
“I am delighted to welcome CHRU de Nancy to the TriNetX global health research network,” said Olivier Denquin, Regional Partnerships Manager France at TriNetX. “We are committed to supporting the university’s investigator-initiated research program, as well as driving industry-sponsored clinical trial opportunities to the university’s patients in need.”
About CHRU de Nancy
With more than 9,600 professionals and 1,300 health students, CHRU de Nancy provides referral and local care missions thanks to quality multidisciplinary medical and surgical expertise at the service of the population, at all ages from the life. The university hospital teams are also involved daily in training, research, innovation, public health and health education missions. CHRU de Nancy is a major player in French clinical research, the doctors‐researchers of CHRU de Nancy have been carrying out high-level research for many years, which attracts funding and positions the establishment on the French, European and international scenes. With more than 900 clinical research protocols in progress, 5,000 patients included in research per year on average and 950 articles published per year (2019 figures), the CHRU de Nancy is considered one of the ten best French health organizations in research. For more information, visit: chu-nancy.fr
About TriNetX, LLC
TriNetX is a global network of healthcare organizations and life sciences companies driving real-world research to accelerate the development of new therapies. Through its self-service, HIPAA, GDPR, and LGPD-compliant platform of federated EHR, datasets, and consulting partnerships, TriNetX puts the power of real-world data into the hands of its worldwide community to improve protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. For more information, visit TriNetX at www.trinetx.com or follow @TriNetX on Twitter.
CHRU de Nancy
+33 (0) 6-33-95-78-48
+1 (857) 285-6038